In a report released today, Hartaj Singh from Oppenheimer maintained a Hold rating on Moderna (MRNA – Research Report). The company’s shares closed yesterday at $86.33.
According to TipRanks, Singh is a 5-star analyst with an average return of 11.9% and a 44.49% success rate. Singh covers the Healthcare sector, focusing on stocks such as Moderna, Regeneron, and Gilead Sciences.
Moderna has an analyst consensus of Moderate Buy, with a price target consensus of $160.61.
See Insiders’ Hot Stocks on TipRanks >>
MRNA market cap is currently $32.86B and has a P/E ratio of 31.72.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Moderna (MRNA) Company Description:
Incorporated in 2010, Massachusetts-based Moderna, Inc. is a clinical stage biotechnology company which develops therapeutics and vaccines based on messenger ribonucleic acid (mRNA) for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
Read More on MRNA:
